<DOC>
	<DOCNO>NCT00753727</DOCNO>
	<brief_summary>This research do aim develop effective treatment standard radiotherapy surgery alone . Although standard treatment frequently successful , patient respond well treatment . Low oxygen level tumour , may particular problem sarcoma , think one factor contribute failure radiotherapy . Sunitinib new drug active cell low oxygen level . The combination sunitinib radiotherapy show promising result cancer . The purpose study find whether treatment new drug , sunitinib , increase effectiveness radiotherapy kill cancer cell ; test safety combination sunitinib radiotherapy .</brief_summary>
	<brief_title>Sunitinib Radiation Patients With Resectable Soft-tissue Sarcoma</brief_title>
	<detailed_description>The presence hypoxia document soft-tissue sarcoma , may contribute radioresistance . Combinations radiosensitisers ifosfamide doxorubicin radiotherapy demonstrate promise sarcoma , significant toxicity . The rationale study base : - frequency hypoxia soft-tissue sarcoma - importance radiotherapy neoadjuvant treatment soft-tissue sarcoma - target hypoxic vasculature sunitinib - single agent activity sunitinib soft-tissue sarcoma . This study assess feasibility tolerability combination sunitinib standard preoperative radiotherapy . The surrogate endpoint tumor necrosis functional RECIST image response provide early evidence response rate . Toxicities assess chemoradiation follow surgery . The impact treatment hypoxic component tumor investigate F18 azamycin arabinoside PET scan . Because combination sunitinib radiotherapy study , propose phase Ib design dose reduction event excessive toxicity . Sunitinib treatment precede commencement radiotherapy 2 week preclinical evidence prim tumor vasculature may increase synergy radiotherapy , sunitinib may single agent activity sarcoma , include measurable effect tumor vasculature . Because anticipated likelihood complication attributable combination sunitinib radiotherapy small , start dose sunitinib 50mg/day two week lead-in period 25mg 5 week concurrent radiotherapy .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically confirm softtissue sarcoma suitable neoadjuvant radiotherapy surgery minimum age 16 year ECOG performance status =1 life expectancy great 6 month patient must normal organ marrow function evidence bleed thrombotic tendency , evidence arterial venous thrombosis pregnant breastfeeding ability give write informed consent . Softtissue sarcoma locate site radiotherapy associate significant exposure abdominal viscera patient invasive malignancy , exception nonmelanoma skin cancer , last 5 year patient receive therapeutic investigational agent patient receive concurrent treatment anticancer therapy evidence distant metastasis uncontrolled intercurrent illness patient pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>soft tissue</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>radiotherapy</keyword>
</DOC>